SDGR
Schrödinger, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
19.55
▼ 0.03 (0.15%)
MARKET · —
Price
Open
19.45
Prev close
19.58
Day high
20.48
Day low
19.51
Volume
1.08M
Market cap
$1.47B
P/E (TTM)
—
52W range
10.95 – 23.02
Trailing performance
Returnvs SPY
1W
+12.05%
+13.4%
1M
+30.27%
+26.5%
3M
+48.98%
+45.9%
6M
+70.95%
+59.9%
YTD
+10.23%
-2.1%
1Y
+1.81%
-18.2%
3Y
-43.18%
-117.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.47B
Enterprise value$1.17B
Revenue (TTM)$259.04M
Gross profit$147.31M
EBITDA$-147.58M
Net income$-54.34M
EPS (TTM)$-0.73
Free cash flow$-29.16M
Total cash$413.74M
Total debt$108.00M
Book value / share$4.51
Shares outstanding65.64M
Float57.33M
Short % of float26.23%
Dividend yield—
Beta (5Y)1.66
Valuation & profitability ratios
Trailing P/E—
Forward P/E-14.60
PEG ratio—
Price / sales—
Price / book4.37
EV / revenue4.51
EV / EBITDA-7.92
Gross margin56.87%
Operating margin-70.55%
Profit margin-20.98%
Return on equity-16.17%
Return on assets-14.44%
Debt / equity32.83
Current ratio2.71
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $255.87M | $207.54M | $216.70M | $181.00M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$103.27M | -$187.12M | $40.72M | -$149.20M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$103.27M | -$187.12M | $40.72M | -$149.20M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.67 | -0.42 | +37.9% |
| Mar 2026 | -0.57 | -0.62 | -8.9% |
| Dec 2025 | -0.09 | -0.18 | -100.2% |
| Sep 2025 | -0.74 | -0.57 | +23.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.52 | 1 | $48.55M | -10.6% |
| Next quarter | -0.16 | 1 | $74.68M | -14.4% |
| Current year | -1.83 | 1 | $242.72M | -5.1% |
| Next year | -1.35 | 1 | $250.30M | +3.1% |
Analyst targets & ownership
Mean target$21.43
High target$30.00
Low target$17.00
Implied upside9.61%
Analyst count7
ConsensusBUY
Strong buy / Buy0 / 5
Hold2
Sell / Strong sell0 / 0
Held by insiders3.00%
Held by institutions96.66%
Institutions holding319
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+1.29M
Net buying
Buy transactions
20
1.40M shares
Sell transactions
12
107.14K shares
Net transactions
+32
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
2.25M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 16, 26 | JAIN RACHIT Chief Financial Officer |
SELL | 875 | $13.65K | Direct |
| Jun 26, 26 | FRIESNER RICHARD A Director |
STOCK | 679.37K | $0 | Indirect |
| Jun 22, 26 | LYNTON MICHAEL M Director |
STOCK | 8.14K | $0 | Direct |
| Jun 22, 26 | GINSBERG GARY L Director |
STOCK | 8.14K | $0 | Direct |
| Jun 22, 26 | OBEROI ARUN Director |
STOCK | 8.14K | $0 | Direct |
| Jun 22, 26 | VAN KRALINGEN BRIDGET ANNE Director |
STOCK | 8.14K | $0 | Direct |
| Jun 22, 26 | CHODAKEWITZ JEFFREY A. M.D. Director |
STOCK | 8.14K | $0 | Direct |
| Jun 22, 26 | SENDER GARY L. Director |
STOCK | 8.14K | $0 | Direct |
| Jun 22, 26 | THORNBERRY NANCY A. Director |
STOCK | 8.14K | $0 | Direct |
| Jun 22, 26 | FRIESNER RICHARD A Director |
STOCK | 8.14K | $0 | Direct |
| Jun 22, 26 | KAPELLER-LIBERMANN ROSANA Director |
STOCK | 8.14K | $0 | Direct |
| Apr 17, 26 | RAMY SAMIR FARID PH.D. Chief Executive Officer |
CONVERSION | 160.53K | $492.82K | Direct |
| Apr 17, 26 | RAMY SAMIR FARID PH.D. Chief Executive Officer |
SELL | 86.00K | $1.06M | Direct |
| Apr 16, 26 | JAIN RACHIT Chief Financial Officer |
SELL | 844 | $10.76K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ABEL ROBERT LORNE |
Officer | 55.90K | Sale |
AKINSANYA-AKIWUMI KAREN OLUFUNMILYO |
President | 69.96K | Sale |
AKLIAN MANNIX VARTAN |
Officer | 31.19K | Stock Award(Grant) |
FRIESNER RICHARD A |
Director | — | Stock Gift |
HERMAN JENNY |
Officer | 34.80K | Sale |
JAIN RACHIT |
Chief Financial Officer | 50.88K | Sale |
LORTON KENNETH PATRICK |
Officer | 89.24K | Sale |
PORGES GEOFFREY CRAIG |
Chief Financial Officer | 27.54K | Stock Award(Grant) |
RAMY SAMIR FARID PH.D. |
Chief Executive Officer | 405.35K | Conversion of Exercise of derivative security |
TRAN YVONNE KIM |
Officer | 52.68K | Sale |
Moving averages & technicals
SMA 10
18.63
+4.93% from price
SMA 20
17.29
+14.00% from price
SMA 50
16.38
+20.33% from price
SMA 100
14.58
+34.11% from price
SMA 200
15.02
+31.26% from price
EMA 12
18.34
+6.57% from price
EMA 26
17.39
+12.40% from price
EMA 50
16.46
+18.77% from price
RSI (14)
70.2
Overbought
MACD (12,26,9)
0.95
Hist 0.22
ATR (14)
0.96
4.88% of price
Realised vol 30D
50.8%
Annualised
Bollinger upper
20.60
20, 2σ
Bollinger lower
13.98
20, 2σ
50 / 200 cross
Golden
16.38 vs 15.02
Trend bias
Above 200
+31.26%
Risk profile
Beta vs SPY
1.61
More volatile than market
Correlation to SPY
0.39
Loosely linked
Realised vol 30D
50.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-50.8%
Peak to trough
Max drawdown 5Y
-83.0%
Peak to trough
ATR 14
0.96
4.88% of price
Beta (reported)
1.66
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
0.25
Positioning, not flow
Max pain
12.50
-36.6% from spot
ATM implied vol
57.7%
Nearest strike to spot
Skew (10% OTM)
-0.8%
Calls bid over puts
Call volume
527
Contracts, this expiry
Put volume
91
Contracts, this expiry
Heaviest call OI
20.00
790 contracts
Heaviest put OI
12.50
345 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
Zacks · 4d ago
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Zacks · 5d ago
UBS Adjusts Schrodinger PT to $19 From $13, Maintains Neutral Rating
MT Newswires · 8d ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 8d ago
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
24/7 Wall St. · 11d ago
Schrödinger (SDGR) Is Up 8.5% After AI Co‑Scientist Deal With BMS And Q2 Profitability Shift – Has The Bull Case Changed?
Simply Wall St. · 16d ago
Schrodinger Inc (SDGR) (Q2 2026) Earnings Call Highlights: ACV Surges 27% on Bunsen Launch and ...
GuruFocus.com · 16d ago
Schrodinger Q2 Earnings Call Highlights
MarketBeat · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.